John Lacey | IR |
Philip Serlin | Chief Executive Officer |
Mali Zeevi | Chief Financial Officer |
Holly May | Chief Commercial Officer |
Abi Vainstein-Haras | Chief Medical Officer |
Joe Pantginis | H.C. Wainwright |
Mark Breidenbach | Oppenheimer |
John Vandermosten | Zacks |
Ladies and gentlemen | thank you for standing by. Welcome to the BioLineRx Third Quarter 2022 Results Conference Call. All participants are presently in a listen-only mode. Following management's formal presentation - instructions will be given for the question-and-answer session. [Operator Instructions] |
I would now like to turn over the call to John Lacey | Head of Corporate Communications and Investor Relations. Please go ahead. |
Thank you, operator.
Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements in this conference call, other than historical facts, are indeed forward-looking statements. The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project and other similar expressions are used typically to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and may involve and are subject to certain risks and uncertainties and other factors that may affect BioLineRx's business, financial conditions and other operating results.